EpicGenetics developed and offers the FM/a Test, an FDA-compliant diagnostic blood test that identifies the immune system biomarkers of fibromyalgia.
According to the company, the new facility is 50,000 square feet and located at 11801 West Olympic in Los Angeles.
The move enables the company to expand its lab, support employee growth and facilitate new research initiatives.
In August, the company announced an FDA approved clinical trial that will be held at Massachusetts General Hospital.
The trial will evaluate the potential for BCG (an inexpensive generic vaccine used globally to prevent tuberculosis) to reverse fibromyalgia.
EpicGenetics is a privately held biomedical company based in Los Angeles, California that developed and manufactures the FM/a Test.
The company is dedicated to improving the diagnosis and treatment of fibromyalgia by offering the first conclusive diagnostic test for fibromyalgia, and by investing in and developing further comprehensive clinical studies at leading medical research centers.
Merck launches Phase 3 trial for dengue vaccine candidate V181
BioNet and Bio Farma sign MoU on TdaP vaccine
Dx&Vx accelerates universal COVID-19 vaccine development
Moderna withdraws application for flu-COVID combination vaccine pending additional efficacy data
CTP delivers 18,000 sqm Serbian facility for SCHOTT Pharma to support global expansion
LakeShore Biopharma launches novel packaging solution for YSJA rabies vaccine (Vero cell)
Scancell partners with NHS Cancer Vaccine Launch Pad to accelerate melanoma trial recruitment
Orexo reports positive results for powder-based intranasal vaccine using AmorphOX technology
GC Biopharma's BARYTHRAX receives Korean regulatory approval
GSK grants USD2m to boost adult vaccination efforts
Valneva and LimmaTech begin Phase 2 infant trial for Shigella vaccine candidate S4V2
Circio Holding and Entos Pharmaceuticals collaborate on circular RNA delivery
AKAGERA Medicines completes first cohort in phase 1 SAD/MAD study of AKG-100